KRAS G12C inhibitor

DRUG CLASS:

KRAS G12C inhibitor

News alerts, weekly reports and conference planners

Related drugs:

‹

›

KRAS G12C + KEAP1 mutation	Non Small Cell Lung Cancer	KRAS G12C + KEAP1 mutation	Non Small Cell Lung Cancer	sotorasib Resistant: B - Late Trials ASCO 2023 - 1 week (New B) sotorasib Resistant : B ASCO 2023 - 1wk	sotorasib Resistant: B - Late Trials ASCO 2023 - 1 week sotorasib Resistant : B ASCO 2023 - 1 week - (New B)
KRAS G12C + STK11 mutation	Non Small Cell Lung Cancer	KRAS G12C + STK11 mutation	Non Small Cell Lung Cancer	sotorasib Sensitive: B - Late Trials ASCO 2023 - 1 week (New B) sotorasib Sensitive : B ASCO 2023 - 1wk	sotorasib Sensitive: B - Late Trials ASCO 2023 - 1 week sotorasib Sensitive : B ASCO 2023 - 1 week - (New B)
KRAS G12C + TP53 mutation	Non Small Cell Lung Cancer	KRAS G12C + TP53 mutation	Non Small Cell Lung Cancer	sotorasib Sensitive: B - Late Trials ASCO 2023 - 1 week (New B) sotorasib Sensitive : B ASCO 2023 - 1wk	sotorasib Sensitive: B - Late Trials ASCO 2023 - 1 week sotorasib Sensitive : B ASCO 2023 - 1 week - (New B)
KRAS G12C	Lung Non-Squamous Non-Small Cell Cancer	KRAS G12C	Lung Non-Squamous Non-Small Cell Cancer	sotorasib Sensitive: C1 - Off-label ASCO 2023 - 1 week (New C3) sotorasib Sensitive : C1 ASCO 2023 - 1wk	sotorasib Sensitive: C1 - Off-label ASCO 2023 - 1 week sotorasib Sensitive : C1 ASCO 2023 - 1 week - (New C3)
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	GFH925 Sensitive: C2 – Inclusion Criteria ASCO 2023 - 1 week (New C3) GFH925 Sensitive : C2 ASCO 2023 - 1wk	GFH925 Sensitive: C2 – Inclusion Criteria ASCO 2023 - 1 week GFH925 Sensitive : C2 ASCO 2023 - 1 week - (New C3)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	JDQ443 Sensitive: C2 – Inclusion Criteria ASCO 2023 - 1 week (New C3) JDQ443 Sensitive : C2 ASCO 2023 - 1wk	JDQ443 Sensitive: C2 – Inclusion Criteria ASCO 2023 - 1 week JDQ443 Sensitive : C2 ASCO 2023 - 1 week - (New C3)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	GEC-255 Sensitive: C2 – Inclusion Criteria ASCO 2023 - 1 week (New C3) GEC-255 Sensitive : C2 ASCO 2023 - 1wk	GEC-255 Sensitive: C2 – Inclusion Criteria ASCO 2023 - 1 week GEC-255 Sensitive : C2 ASCO 2023 - 1 week - (New C3)
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	GFH925 Sensitive: C2 – Inclusion Criteria ASCO 2023 - 1 week (New C3) GFH925 Sensitive : C2 ASCO 2023 - 1wk	GFH925 Sensitive: C2 – Inclusion Criteria ASCO 2023 - 1 week GFH925 Sensitive : C2 ASCO 2023 - 1 week - (New C3)
STK11 mutation + KEAP1 mutation + KRAS G12C	Non Small Cell Lung Cancer	STK11 mutation + KEAP1 mutation + KRAS G12C	Non Small Cell Lung Cancer	sotorasib Resistant: C3 – Early Trials ASCO 2023 - 1 week (New C3) sotorasib Resistant : C3 ASCO 2023 - 1wk	sotorasib Resistant: C3 – Early Trials ASCO 2023 - 1 week sotorasib Resistant : C3 ASCO 2023 - 1 week - (New C3)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + OTS514 Sensitive: D – Preclinical J Cell Mol Med - 1 week (New D) sotorasib + OTS514 Sensitive : D J Cell Mol Med - 1wk	sotorasib + OTS514 Sensitive: D – Preclinical J Cell Mol Med - 1 week sotorasib + OTS514 Sensitive : D J Cell Mol Med - 1 week - (New D)
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	D-1553 Sensitive: C2 – Inclusion Criteria Cancer Sci - 3 weeks (New D) D-1553 Sensitive : C2 Cancer Sci - 3wk	D-1553 Sensitive: C2 – Inclusion Criteria Cancer Sci - 3 weeks D-1553 Sensitive : C2 Cancer Sci - 3 weeks - (New D)
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib Sensitive: A1 - Approval sotorasib Sensitive : A1	sotorasib Sensitive: A1 - Approval sotorasib Sensitive : A1
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	adagrasib Sensitive: A1 - Approval adagrasib Sensitive : A1	adagrasib Sensitive: A1 - Approval adagrasib Sensitive : A1
KRAS G12C	Pancreatic Adenocarcinoma	KRAS G12C	Pancreatic Adenocarcinoma	sotorasib Sensitive: A2 - Guideline sotorasib Sensitive : A2	sotorasib Sensitive: A2 - Guideline sotorasib Sensitive : A2
KRAS G12C	Pancreatic Adenocarcinoma	KRAS G12C	Pancreatic Adenocarcinoma	adagrasib Sensitive: A2 - Guideline adagrasib Sensitive : A2	adagrasib Sensitive: A2 - Guideline adagrasib Sensitive : A2
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	cetuximab + adagrasib Sensitive: B - Late Trials cetuximab + adagrasib Sensitive : B	cetuximab + adagrasib Sensitive: B - Late Trials cetuximab + adagrasib Sensitive : B
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + BBP-398 Sensitive: B - Late Trials sotorasib + BBP-398 Sensitive : B	sotorasib + BBP-398 Sensitive: B - Late Trials sotorasib + BBP-398 Sensitive : B
KRAS G12C	Ampulla of Vater Carcinoma	KRAS G12C	Ampulla of Vater Carcinoma	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Pancreatic Cancer	KRAS G12C	Pancreatic Cancer	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Cholangiocarcinoma	KRAS G12C	Cholangiocarcinoma	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Ovarian Cancer	KRAS G12C	Ovarian Cancer	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Pancreatic Cancer	KRAS G12C	Pancreatic Cancer	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Endometrial Cancer	KRAS G12C	Endometrial Cancer	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Melanoma	KRAS G12C	Melanoma	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Endometrial Cancer	KRAS G12C	Endometrial Cancer	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Gastrointestinal Cancer	KRAS G12C	Gastrointestinal Cancer	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1	sotorasib Sensitive: C1 - Off-label sotorasib Sensitive : C1
KRAS G12C	Gastrointestinal Cancer	KRAS G12C	Gastrointestinal Cancer	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Pancreatic Ductal Adenocarcinoma	KRAS G12C	Pancreatic Ductal Adenocarcinoma	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Lung Cancer	KRAS G12C	Lung Cancer	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Biliary Tract Cancer	KRAS G12C	Biliary Tract Cancer	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Lung Cancer	KRAS G12C	Lung Cancer	D-1553 Sensitive: C2 – Inclusion Criteria D-1553 Sensitive : C2	D-1553 Sensitive: C2 – Inclusion Criteria D-1553 Sensitive : C2
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	MEK inhibitor + sotorasib Sensitive: C2 – Inclusion Criteria MEK inhibitor + sotorasib Sensitive : C2	MEK inhibitor + sotorasib Sensitive: C2 – Inclusion Criteria MEK inhibitor + sotorasib Sensitive : C2
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	GFH925 Sensitive: C2 – Inclusion Criteria GFH925 Sensitive : C2	GFH925 Sensitive: C2 – Inclusion Criteria GFH925 Sensitive : C2
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	JAB-21822 Sensitive: C2 – Inclusion Criteria JAB-21822 Sensitive : C2	JAB-21822 Sensitive: C2 – Inclusion Criteria JAB-21822 Sensitive : C2
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	D-1553 Sensitive: C2 – Inclusion Criteria D-1553 Sensitive : C2	D-1553 Sensitive: C2 – Inclusion Criteria D-1553 Sensitive : C2
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	RG6330 Sensitive: C2 – Inclusion Criteria RG6330 Sensitive : C2	RG6330 Sensitive: C2 – Inclusion Criteria RG6330 Sensitive : C2
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	RG6330 Sensitive: C2 – Inclusion Criteria RG6330 Sensitive : C2	RG6330 Sensitive: C2 – Inclusion Criteria RG6330 Sensitive : C2
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	RG6330 Sensitive: C2 – Inclusion Criteria RG6330 Sensitive : C2	RG6330 Sensitive: C2 – Inclusion Criteria RG6330 Sensitive : C2
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	GFH925 Sensitive: C2 – Inclusion Criteria GFH925 Sensitive : C2	GFH925 Sensitive: C2 – Inclusion Criteria GFH925 Sensitive : C2
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	JAB-21822 Sensitive: C2 – Inclusion Criteria JAB-21822 Sensitive : C2	JAB-21822 Sensitive: C2 – Inclusion Criteria JAB-21822 Sensitive : C2

KRAS G12C inhibitor

KRAS G12C inhibitor

Associations(119)

Associations
(119)